Liquidia

Treprostinil Platform Expansion Into Lung Diseases Will Drive Powerful Long Term Upside

AnalystHighTarget

Not Invested

Community Contributor

Published

08 Dec 25

Views

08 Dec

US$61.85

AnalystHighTarget's Fair Value

US$67.00

7.7% undervalued

241.0%

-0.02%

241.0%

-0.02%

You can edit this narrative until Dec 9 6:05 PM. Then, changes will post as Updates.

Author's Valuation

US$677.7% undervalued

AnalystHighTarget Fair Value

Valuator

Company Info

Notes

AnalystHighTarget Fair Value

US$67

7.7% undervalued

Future estimation in

Revenue

Profit Margin

Future PE

Est. Revenue

Forecast revenue growth rate

25.10%

Historical revenue growth rate

66.85%

Pharma revenue growth rate

0.48%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.11%

Calculation

US$494.33m

Earnings '28

12.53x

PE Ratio '28

US$6.20b

Market Cap '28

US$6.20b

Market Cap '28

92.29m

No. shares '28

US$67.14

Share Price '28

US$67.14 Share Price '28

Discounted to 2025 @ 0.07% p.a.

US$67.00

Fair Value '25